Daniel Jacoby, MD

• Alexander Thomas
• Allen Hsiao
• Allison E. Gaffey
• Amarnath Annapureddy
• Andrew Philip Notarianni
• Angela Maria Victoria-Castro
• Ania Jastreboff
• Brenda Cabrera-Mendoza
• Caihong Qiu
• Carlos Mena-Hurtado
• Christopher Maulion
• David Mulligan
• Edward J Miller
• F. Perry Wilson
• Fangyong Li
• Forrester Lee
• Garrett Ash
• Gita Pathak
• Harlan Krumholz
• Jacqueline Geer
• James V. Freeman
• Jeffrey Testani
• Jeffrey Turner
• Jeptha Curtis
• Karl Minges
• Katherine Clark
• Kim Germaine Emiel Smolderen
• Lawrence Young
• Makoto Mori
• Michael Fuery
• Muhammad Riaz
• Pramod Bonde
• Ralph J. Riello
• Renato Polimanti
• Robert Elder
• Rohan Khera
• Samuel Reinhardt
• Sounok Sen
• Stuart Campbell
• Tariq Ahmad
• Veena Rao
• Wade Schulz
• Yibing Qyang

Amyloidosis; Genetics; Heart Failure; Sleep; Heart Transplantation; Clinical Trial

• Correlates of cognition among people with chronic heart failure and insomniaGeer JH, Jeon S, O’Connell M, Linsky S, Conley S, Hollenbeak CS, Jacoby D, Yaggi HK, Redeker NS. Correlates of cognition among people with chronic heart failure and insomnia. Sleep And Breathing 2022, 27: 1287-1296. PMID: 36214945, PMCID: PMC10084469, DOI: 10.1007/s11325-022-02716-w.
• The Yale Roadmap for Health Psychology and Integrated Cardiovascular CareGaffey AE, Harris KM, Mena-Hurtado C, Sinha R, Jacoby DL, Smolderen KG. The Yale Roadmap for Health Psychology and Integrated Cardiovascular Care. Health Psychology 2022, 41: 779-791. PMID: 35201804, DOI: 10.1037/hea0001152.
• Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementationVictoria‐Castro A, Martin M, Yamamoto Y, Ahmad T, Arora T, Calderon F, Desai N, Gerber B, Lee KA, Jacoby D, Melchinger H, Nguyen A, Shaw M, Simonov M, Williams A, Weinstein J, Wilson FP. Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology 2022, 45: 839-849. PMID: 35822275, PMCID: PMC9346973, DOI: 10.1002/clc.23848.
• Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registryGimeno JR, Olivotto I, Rodríguez AI, Ho CY, Fernández A, Quiroga A, Espinosa MA, Gómez‐González C, Robledo M, Tojal‐Sierra L, Day SM, Owens A, Barriales‐Villa R, Larrañaga JM, Rodríguez‐Palomares J, González‐del‐Hoyo M, Piqueras‐Flores J, Reza N, Chumakova O, Ashley EA, Parikh V, Wheeler M, Jacoby D, Pereira AC, Saberi S, Helms AS, Villacorta E, Gallego‐Delgado M, de Castro D, Domínguez F, Ripoll‐Vera T, Zorio‐Grima E, Sánchez‐Martínez J, García‐Álvarez A, Arbelo E, Mogollón MV, Fuentes‐Cañamero M, Grande E, Peña C, Monserrat L, Lakdawala NK, Muñoz‐Esparza C, García‐Pinilla J, Robles‐Mezcua A, Moreno‐Flores M, Peña M, Merlo M, Cubillo D, Climent‐Payá V, Dankovtseva E, Vilela A, García‐Pavía P, Casas G. Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure 2022, 9: 2189-2198. PMID: 36255281, PMCID: PMC9288745, DOI: 10.1002/ehf2.13964.
• Aligning mission to digital health strategy in academic medical centersCohen AB, Stump L, Krumholz HM, Cartiera M, Jain S, Scott Sussman L, Hsiao A, Lindop W, Ying AK, Kaul RL, Balcezak TJ, Tereffe W, Comerford M, Jacoby D, Navai N. Aligning mission to digital health strategy in academic medical centers. Npj Digital Medicine 2022, 5: 67. PMID: 35654885, PMCID: PMC9163186, DOI: 10.1038/s41746-022-00608-7.
• Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyondMorelli C, Ingrasciotta G, Jacoby D, Masri A, Olivotto I. Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. European Journal Of Internal Medicine 2022, 102: 1-7. PMID: 35534374, DOI: 10.1016/j.ejim.2022.04.020.
• Sleep Characteristics, Mood, Somatic Symptoms, and Self-Care Among People With Heart Failure and InsomniaBreazeale S, Jeon S, Hwang Y, O’Connell M, Nwanaji-Enwerem U, Linsky S, Yaggi HK, Jacoby DL, Conley S, Redeker NS. Sleep Characteristics, Mood, Somatic Symptoms, and Self-Care Among People With Heart Failure and Insomnia. Nursing Research 2022, 71: 189-199. PMID: 35149627, PMCID: PMC9038676, DOI: 10.1097/nnr.0000000000000585.
• Symptom Cluster Profiles Among Adults with Insomnia and Heart FailureConley S, Jeon S, Breazeale S, O’Connell M, Hollenbeak CS, Jacoby D, Linsky S, Yaggi HK, Redeker NS. Symptom Cluster Profiles Among Adults with Insomnia and Heart Failure. Behavioral Sleep Medicine 2022, 21: 150-161. PMID: 35388730, PMCID: PMC9537348, DOI: 10.1080/15402002.2022.2060226.
• Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic CardiomyopathyRiaz M, Park J, Sewanan LR, Ren Y, Schwan J, Das SK, Pomianowski PT, Huang Y, Ellis MW, Luo J, Liu J, Song L, Chen IP, Qiu C, Yazawa M, Tellides G, Hwa J, Young LH, Yang L, Marboe CC, Jacoby DL, Campbell SG, Qyang Y. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. Circulation 2022, 145: 1238-1253. PMID: 35384713, PMCID: PMC9109819, DOI: 10.1161/circulationaha.121.056265.
• Automated multilabel diagnosis on electrocardiographic images and signalsSangha V, Mortazavi BJ, Haimovich AD, Ribeiro AH, Brandt CA, Jacoby DL, Schulz WL, Krumholz HM, Ribeiro ALP, Khera R. Automated multilabel diagnosis on electrocardiographic images and signals. Nature Communications 2022, 13: 1583. PMID: 35332137, PMCID: PMC8948243, DOI: 10.1038/s41467-022-29153-3.
• Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathyHiggins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.
• The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expressionPathak GA, De Lillo A, Wendt FR, De Angelis F, Koller D, Mendoza B, Jacoby D, Miller EJ, Buxbaum JN, Polimanti R. The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression. Amyloid 2021, 29: 110-119. PMID: 34935565, PMCID: PMC9213571, DOI: 10.1080/13506129.2021.2018678.
• Impact of Obesity on Heart Transplantation OutcomesChouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10: e021346. PMID: 34854316, PMCID: PMC9075353, DOI: 10.1161/jaha.121.021346.
• Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic CardiomyopathyHegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal Of The American College Of Cardiology 2021, 78: 2518-2532. PMID: 34915982, DOI: 10.1016/j.jacc.2021.09.1381.
• Cognitive behavioral therapy for insomnia has sustained effects on insomnia, fatigue, and function among people with chronic heart failure and insomnia: the HeartSleep StudyRedeker NS, Yaggi HK, Jacoby D, Hollenbeak CS, Breazeale S, Conley S, Hwang Y, Iennaco J, Linsky S, Nwanaji-Enwerem U, O’Connell M, Jeon S. Cognitive behavioral therapy for insomnia has sustained effects on insomnia, fatigue, and function among people with chronic heart failure and insomnia: the HeartSleep Study. Sleep 2021, 45: zsab252. PMID: 34657160, PMCID: PMC8754495, DOI: 10.1093/sleep/zsab252.
• Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.Nauffal V, Marstrand P, Han L, Parikh VN, Helms AS, Ingles J, Jacoby D, Lakdawala NK, Kapur S, Michels M, Owens AT, Ashley EA, Pereira AC, Rossano JW, Saberi S, Semsarian C, Ware JS, Wittekind SG, Day S, Olivotto I, Ho CY. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal 2021, 42: 3932-3944. PMID: 36282238, DOI: 10.1093/eurheartj/ehab598.
• Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathyNauffal V, Marstrand P, Han L, Parikh VN, Helms AS, Ingles J, Jacoby D, Lakdawala NK, Kapur S, Michels M, Owens AT, Ashley EA, Pereira AC, Rossano JW, Saberi S, Semsarian C, Ware JS, Wittekind SG, Day S, Olivotto I, Ho CY. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal 2021, 42: 3932-3944. PMID: 34491319, PMCID: PMC8497072, DOI: 10.1093/eurheartj/ehab598.
• Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutationSewanan LR, Park J, Rynkiewicz MJ, Racca AW, Papoutsidakis N, Schwan J, Jacoby DL, Moore JR, Lehman W, Qyang Y, Campbell SG. Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. The Journal Of General Physiology 2021, 153: e202012640. PMID: 34319370, PMCID: PMC8321830, DOI: 10.1085/jgp.202012640.
• Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMRKramer CM, DiMarco JP, Kolm P, Ho CY, Desai MY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Maron MS, Appelbaum E, Jerosch-Herold M, Friedrich MG, Schulz-Menger J, Piechnik SK, Mahmod M, Jacoby D, White J, Chiribiri A, Helms A, Choudhury L, Michels M, Bradlow W, Salerno M, Dawson DK, Weinsaft JW, Berry C, Nagueh SF, Buccarelli-Ducci C, Owens A, Casadei B, Watkins H, Weintraub WS, Neubauer S, Investigators H. Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR. JACC Clinical Electrophysiology 2021, 7: 1376-1386. PMID: 34217663, PMCID: PMC8605982, DOI: 10.1016/j.jacep.2021.04.004.
• Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TMCowger JA, Estep JD, Rinde-Hoffman DA, Givertz MM, Anderson AS, Jacoby D, Chen L, Brieke A, Mahr C, Hall S, Ewald GA, Dirckx N, Baker AT, Pinney SP. Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM. ASAIO Journal 2021, 68: 374-383. PMID: 34172641, DOI: 10.1097/mat.0000000000001497.
• Danicamtiv Enhances Systolic Function and Frank‐Starling Behavior at Minimal Diastolic Cost in Engineered Human MyocardiumShen S, Sewanan LR, Jacoby DL, Campbell SG. Danicamtiv Enhances Systolic Function and Frank‐Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium. Journal Of The American Heart Association 2021, 10: e020860. PMID: 34096321, PMCID: PMC8477869, DOI: 10.1161/jaha.121.020860.
• Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialSpertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2021, 397: 2467-2475. PMID: 34004177, DOI: 10.1016/s0140-6736(21)00763-7.
• Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin UseWendt FR, Koller D, Pathak GA, Jacoby D, Miller EJ, Polimanti R. Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clinical Pharmacology & Therapeutics 2021, 110: 777-785. PMID: 33837531, PMCID: PMC8376807, DOI: 10.1002/cpt.2260.
• Genetic and Phenotypic Landscape of Peripartum CardiomyopathyGoli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, DePalma S, Haghighi A, Seidman JG, Seidman CE, Jacoby D, Macones G, Judge DP, Rana S, Margulies KB, Cappola TP, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Alexis JD, Boehmer J, Kamiya C, Gustafsson F, Damm P, Ersbøll AS, Goland S, Hilfiker-Kleiner D, McNamara DM, Investigators T, Arany Z. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation 2021, 143: 1852-1862. PMID: 33874732, PMCID: PMC8113098, DOI: 10.1161/circulationaha.120.052395.
• Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretationThompson AD, Helms AS, Kannan A, Yob J, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Mazzarotto F, Olivotto I, Ho CY, Day SM. Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics In Medicine 2021, 23: 1281-1287. PMID: 33782553, PMCID: PMC8257482, DOI: 10.1038/s41436-021-01134-9.
• Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathyMarston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, Colan SD, Rossano JW, Wittekind SG, Ware JS, Saberi S, Helms AS, Ho CY. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal 2021, 42: 1988-1996. PMID: 33769460, PMCID: PMC8139852, DOI: 10.1093/eurheartj/ehab148.
• Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation PolicyMullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, Mulligan D, Formica R, Rogers JG, Desai NR, Ahmad T. Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC Heart Failure 2021, 9: 420-429. PMID: 33714748, DOI: 10.1016/j.jchf.2021.01.010.
• Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathiesChouairi F, Mullan CW, Sen S, Mori M, Fuery M, Elder RW, Lesse J, Norton K, Clark KA, Miller PE, Mulligan D, Formica R, Rogers JG, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T. Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLOS ONE 2021, 16: e0247789. PMID: 33651802, PMCID: PMC7924739, DOI: 10.1371/journal.pone.0247789.
• Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' replyJacoby D, Ho CY, Lester SJ, Wang A, Olivotto I. Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply. The Lancet 2021, 397: 369-370. PMID: 33516332, DOI: 10.1016/s0140-6736(20)32391-6.
• Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic CardiomyopathyLakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, Ingles J, Semsarian C, Jacoby D, Jefferies JL, Colan SD, Pereira AC, Rossano JW, Wittekind S, Ware JS, Saberi S, Helms AS, Cirino AL, Leinwand LA, Seidman CE, Ho CY. Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic And Precision Medicine 2020, 14: e003062. PMID: 33284039, DOI: 10.1161/circgen.120.003062.
• Psychological stress in heart failure: a potentially actionable disease modifierHarris KM, Jacoby DL, Lampert R, Soucier RJ, Burg MM. Psychological stress in heart failure: a potentially actionable disease modifier. Heart Failure Reviews 2020, 26: 561-575. PMID: 33215323, PMCID: PMC8026548, DOI: 10.1007/s10741-020-10056-8.
• Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySaberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, Sehnert AJ, Kwong RY, Jerosch-Herold M, Masri A, Owens A, Lakdawala NK, Kramer CM, Sherrid M, Seidler T, Wang A, Sedaghat-Hamedani F, Meder B, Havakuk O, Jacoby D. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy. Circulation 2020, 143: 606-608. PMID: 33190524, DOI: 10.1161/circulationaha.120.052359.
• Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure PatientsConley S, O’Connell M, Linsky S, Moemeka L, Darden JW, Gaiser EC, Jacoby D, Yaggi H, Redeker NS. Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure Patients. Western Journal Of Nursing Research 2020, 43: 785-790. PMID: 33158412, PMCID: PMC8099934, DOI: 10.1177/0193945920970229.
• Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device PlacementStawiarski K, Agboola O, Park J, Geirsson A, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Lee F, Mangi A, Bonde P. Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal 2020, 67: 650-657. PMID: 33074860, DOI: 10.1097/mat.0000000000001289.
• Day-to-day Relationships between Physical Activity and Sleep Characteristics among People with Heart Failure and InsomniaAsh G, Jeon S, Conley S, Knies AK, Yaggi HK, Jacoby D, Hollenbeak CS, Linsky S, O’Connell M, Redeker NS. Day-to-day Relationships between Physical Activity and Sleep Characteristics among People with Heart Failure and Insomnia. Behavioral Sleep Medicine 2020, 19: 602-614. PMID: 33048589, PMCID: PMC8496686, DOI: 10.1080/15402002.2020.1824918.
• Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditionsZhang X, Walsh R, Whiffin N, Buchan R, Midwinter W, Wilk A, Govind R, Li N, Ahmad M, Mazzarotto F, Roberts A, Theotokis PI, Mazaika E, Allouba M, de Marvao A, Pua CJ, Day SM, Ashley E, Colan SD, Michels M, Pereira AC, Jacoby D, Ho CY, Olivotto I, Gunnarsson GT, Jefferies JL, Semsarian C, Ingles J, O’Regan D, Aguib Y, Yacoub MH, Cook SA, Barton PJR, Bottolo L, Ware JS. Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics In Medicine 2020, 23: 69-79. PMID: 33046849, PMCID: PMC7790749, DOI: 10.1038/s41436-020-00972-3.
• Temporal Trend of Age at Diagnosis in Hypertrophic CardiomyopathyCanepa M, Fumagalli C, Tini G, Vincent-Tompkins J, Day SM, Ashley EA, Mazzarotto F, Ware JS, Michels M, Jacoby D, Ho CY, Olivotto I, Investigators T. Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation Heart Failure 2020, 13: e007230-e007230. PMID: 32894986, PMCID: PMC7497482, DOI: 10.1161/circheartfailure.120.007230.
• Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation SystemMori M, Wilson L, Ali A, Ahmad T, Anwer M, Jacoby D, Geirsson A, Krumholz HM. Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. JAMA Network Open 2020, 3: e2017513. PMID: 32945877, PMCID: PMC7501535, DOI: 10.1001/jamanetworkopen.2020.17513.
• Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid CardiomyopathyHiggins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.
• Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialOlivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D, investigators E, Bartunek J, Bondue A, Van Craenenbroeck E, Kubanek M, Zemanek D, Jensen M, Mogensen J, Thune J, Charron P, Hagege A, Lairez O, Trochu J, Axthelm C, Duengen H, Frey N, Mitrovic V, Preusch M, Schulz-Menger J, Seidler T, Arad M, Halabi M, Katz A, Monakier D, Paz O, Viskin S, Zwas D, Olivotto I, Rocca H, Michels M, Dudek D, Oko-Sarnowska Z, Oreziak A, Wojakowski W, Cardim N, Pereira H, Barriales-Villa R, Pavia P, Blanes J, Urbano R, Diaz L, Elliott P, Yousef Z, Abraham T, Afshar K, Alvarez P, Bach R, Becker R, Choudhury L, Fermin D, Jacoby D, Jefferies J, Kramer C, Lakdawala N, Lester S, Marian A, Masri A, Maurer M, Nagueh S, Owens A, Owens D, Rader F, Saberi S, Sherrid M, Shirani J, Symanski J, Turer A, Wang A, Wever-Pinzon O, Wheeler M, Wong T, Yamani M. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2020, 396: 759-769. PMID: 32871100, DOI: 10.1016/s0140-6736(20)31792-x.
• Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients with Hypertrophic CardiomyopathyHelms AS, Thompson AD, Glazier AA, Hafeez N, Kabani S, Rodriguez J, Yob JM, Woolcock H, Mazzarotto F, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Olivotto I, Ho CY, Day SM. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients with Hypertrophic Cardiomyopathy. Circulation Genomic And Precision Medicine 2020, 13: 396-405. PMID: 32841044, PMCID: PMC7676622, DOI: 10.1161/circgen.120.002929.
• Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant OutcomesIvey-Miranda JB, Kunnirickal S, Bow L, Maulion C, Testani JM, Jacoby D, Kransdorf EP, Bellumkonda L. Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes. Journal Of Cardiac Failure 2020, 27: 40-47. PMID: 32750489, DOI: 10.1016/j.cardfail.2020.07.012.
• Study Design and Rationale of EXPLORER-HCMHo CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, Waldman CB, Zhang D, Sehnert AJ, Heitner SB. Study Design and Rationale of EXPLORER-HCM. Circulation Heart Failure 2020, 13: e006853. PMID: 32498620, DOI: 10.1161/circheartfailure.120.006853.
• Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyHo CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. Journal Of The American College Of Cardiology 2020, 75: 2649-2660. PMID: 32466879, DOI: 10.1016/j.jacc.2020.03.064.
• Empagliflozin in Heart FailureGriffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.
• Perceived Stress, Subjective, and Objective Symptoms of Disturbed Sleep in Men and Women with Stable Heart FailureGaffey AE, Jeon S, Conley S, Jacoby D, Ash GI, Yaggi HK, O’Connell M, Linsky SJ, Redeker NS. Perceived Stress, Subjective, and Objective Symptoms of Disturbed Sleep in Men and Women with Stable Heart Failure. Behavioral Sleep Medicine 2020, 19: 363-377. PMID: 32394733, PMCID: PMC7658015, DOI: 10.1080/15402002.2020.1762601.
• Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular CardiomyopathySmith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, Agarwal PP, Arscott P, Dellefave-Castillo LM, Vorovich EE, Nutakki K, Wilsbacher LD, Priori SG, Jacoby DL, McNally EM, Helms AS. Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation 2020, 141: 1872-1884. PMID: 32372669, PMCID: PMC7286080, DOI: 10.1161/circulationaha.119.044934.
• Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patientsSchonberger RB, Vallurupalli V, Matlin H, Blitz D, Nwozuzu A, Barron B, Zhang Y, Dai F, Jacoby D, Nasir K, Bardia A. Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. Preventive Medicine Reports 2020, 18: 101085. PMID: 32368435, PMCID: PMC7190748, DOI: 10.1016/j.pmedr.2020.101085.
• Zinc Deficiency as a Reversible Cause of Heart Failure.Rosenblum H, Bikdeli B, Wessler J, Gupta A, Jacoby DL. Zinc Deficiency as a Reversible Cause of Heart Failure. Texas Heart Institute Journal 2020, 47: 152-154. PMID: 32603465, PMCID: PMC7328074, DOI: 10.14503/thij-17-6586.
• Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights from the SHaRe RegistryMarstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, Pereira AC, Wittekind SG, Helms A, Saberi S, Jacoby D, Ware JS, Colan SD, Semsarian C, Ingles J, Lakdawala NK, Ho CY. Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights from the SHaRe Registry. Circulation 2020, 141: 1371-1383. PMID: 32228044, PMCID: PMC7182243, DOI: 10.1161/circulationaha.119.044366.
• Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter studyNazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. Heart Rhythm 2020, 17: 1107-1114. PMID: 32084597, PMCID: PMC8052990, DOI: 10.1016/j.hrthm.2020.02.008.
• Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s ExperienceGriffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, D'Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s Experience. JACC Heart Failure 2020, 8: 199-208. PMID: 32035891, PMCID: PMC7814403, DOI: 10.1016/j.jchf.2019.10.012.
• Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyToepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, Sharma A, Agarwal R, Ewoldt JF, Cloonan P, Letendre J, Lun M, Olivotto I, Colan S, Ashley E, Jacoby D, Michels M, Redwood CS, Watkins HC, Day SM, Staples JF, Padrón R, Chopra A, Ho CY, Chen CS, Pereira AC, Seidman JG, Seidman CE. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation 2020, 141: 828-842. PMID: 31983222, PMCID: PMC7077965, DOI: 10.1161/circulationaha.119.042339.
• Access and Outcomes Among Hypertrophic Cardiomyopathy Patients in a Large Integrated Health SystemThomas A, Papoutsidakis N, Spatz E, Testani J, Soucier R, Chou J, Ahmad T, Darr U, Hu X, Li F, Chen ME, Bellumkonda L, Sumathipala A, Jacoby D. Access and Outcomes Among Hypertrophic Cardiomyopathy Patients in a Large Integrated Health System. Journal Of The American Heart Association 2020, 9: e014095. PMID: 31973610, PMCID: PMC7033886, DOI: 10.1161/jaha.119.014095.
• Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic CardiomyopathyEberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, Rossano JW, Semsarian C, Pereira AC, Olivotto I, Ingles J, Seidman CE, Channaoui N, Cirino AL, Han L, Ho CY, Lakdawala NK. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2020, 5: 83-91. PMID: 31799990, PMCID: PMC6902181, DOI: 10.1001/jamacardio.2019.4638.
• Association of Obesity With Adverse Long-term Outcomes in Hypertrophic CardiomyopathyFumagalli C, Maurizi N, Day SM, Ashley EA, Michels M, Colan SD, Jacoby D, Marchionni N, Vincent-Tompkins J, Ho CY, Olivotto I. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology 2020, 5: 65-72. PMID: 31693057, PMCID: PMC6865784, DOI: 10.1001/jamacardio.2019.4268.
• Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection FractionAngraal S, Mortazavi BJ, Gupta A, Khera R, Ahmad T, Desai NR, Jacoby DL, Masoudi FA, Spertus JA, Krumholz HM. Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure 2019, 8: 12-21. PMID: 31606361, DOI: 10.1016/j.jchf.2019.06.013.
• Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradationNg R, Manring H, Papoutsidakis N, Albertelli T, Tsai N, See CJ, Li X, Park J, Stevens TL, Bobbili PJ, Riaz M, Ren Y, Stoddard CE, Janssen PM, Bunch TJ, Hall SP, Lo YC, Jacoby DL, Qyang Y, Wright N, Ackermann MA, Campbell SG. Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation. JCI Insight 2019, 5 PMID: 31194698, PMCID: PMC6675562, DOI: 10.1172/jci.insight.128643.
• Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy CardiomyocytesSewanan LR, Schwan J, Kluger J, Park J, Jacoby DL, Qyang Y, Campbell SG. Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy Cardiomyocytes. JACC Basic To Translational Science 2019, 4: 495-505. PMID: 31468004, PMCID: PMC6712054, DOI: 10.1016/j.jacbts.2019.03.004.
• Mulibrey Nanism Syndrome: A Case for Heart TransplantationAnwer M, Bin Mahmood SU, Stawiarski K, Elder R, Ali A, Jacoby D. Mulibrey Nanism Syndrome: A Case for Heart Transplantation. The Annals Of Thoracic Surgery 2019, 109: e115-e117. PMID: 31260650, DOI: 10.1016/j.athoracsur.2019.05.021.
• Advanced Cardiac Imaging and the Complexity of Diagnosing Cardiac SarcoidosisMiller EJ, Jacoby D. Advanced Cardiac Imaging and the Complexity of Diagnosing Cardiac Sarcoidosis. Circulation Cardiovascular Imaging 2019, 12: e009275. PMID: 31177819, DOI: 10.1161/circimaging.119.009275.
• Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentationVischer AS, Castelletti S, Syrris P, Bastiaenen R, Miles C, Akdis D, Denhaerynck K, Jacoby D, Saguner AM, Krahn AD, Behr ER, McKenna WJ, Pantazis A. Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. International Journal Of Cardiology 2019, 290: 100-105. PMID: 31104822, DOI: 10.1016/j.ijcard.2019.04.090.
• Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M, Sehnert AJ. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Annals Of Internal Medicine 2019, 170: 741-748. PMID: 31035291, DOI: 10.7326/m18-3016.
• Prediction of ventricular arrhythmia and sudden death in arrhythmogenic right ventricular cardiomyopathy.McKenna WJ, Asaad NA, Jacoby DL. Prediction of ventricular arrhythmia and sudden death in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal 2019, 40: 1859-1861. PMID: 30977786, DOI: 10.1093/eurheartj/ehz195.
• Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitudePapoutsidakis N, Heitner S, Ingles J, Semsarian C, Mannello M, Salberg L, Waldman C, Vaccaro B, Maurizi N, Olivotto I, Jacoby D. Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. American Heart Journal 2019, 214: 28-35. PMID: 31152873, DOI: 10.1016/j.ahj.2019.04.001.
• Response by Ho et al to Letter Regarding Article, “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)”Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Lakdawala NK, Ware JS, Helms AS, Colan SD, Seidman CE, Olivotto I, Investigators F. Response by Ho et al to Letter Regarding Article, “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)”. Circulation 2019, 139: 1559-1560. PMID: 30883221, PMCID: PMC6445361, DOI: 10.1161/circulationaha.118.039069.
• Effects of Cognitive Behavioral Therapy for Insomnia on Sleep, Symptoms, Stress, and Autonomic Function Among Patients With Heart FailureRedeker NS, Conley S, Anderson G, Cline J, Andrews L, Mohsenin V, Jacoby D, Jeon S. Effects of Cognitive Behavioral Therapy for Insomnia on Sleep, Symptoms, Stress, and Autonomic Function Among Patients With Heart Failure. Behavioral Sleep Medicine 2018, 18: 190-202. PMID: 30461315, PMCID: PMC6529289, DOI: 10.1080/15402002.2018.1546709.
• Outcomes of adults with restrictive cardiomyopathy after heart transplantationDePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. The Journal Of Heart And Lung Transplantation 2012, 31: 1269-1275. PMID: 23079066, DOI: 10.1016/j.healun.2012.09.018.
• Doctors and torture.Jacoby D. Doctors and torture. The New England Journal Of Medicine 2004, 351: 1571-4; author reply 1571-4. PMID: 15473020.